8-KExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Exhibit Filing (Feb 13, 2025)

Filed February 13, 2025For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report on February 13, 2025, to announce its financial results for the fourth quarter and full year ended December 31, 2024. While the 8-K itself does not contain the detailed financial figures, it references an accompanying press release (Exhibit 99.1) which will hold the comprehensive performance data and management's commentary. Investors should refer to this press release for specifics on revenue, profitability, and any forward-looking guidance. This filing serves as Alnylam's official notification of its recent financial performance. Key areas of interest for investors will likely include the performance of its commercial products, pipeline advancements, and the company's overall financial health as it moves into the new fiscal year. The press release will provide the critical details to assess Alnylam's execution against its strategic objectives and its potential for future growth.

Key Highlights

  • 1Alnylam Pharmaceuticals announced Q4 and Full Year 2024 financial results on February 13, 2025.
  • 2The detailed financial results are provided in a press release furnished as Exhibit 99.1 to the 8-K filing.
  • 3Investors need to consult Exhibit 99.1 for specific financial data, including revenue, expenses, and profitability.
  • 4The filing indicates the company's performance for the period ending December 31, 2024.
  • 5Information furnished under Item 2.02 is generally not considered 'filed' for liability purposes under Section 18 of the Exchange Act, but investors should be aware of its content.
  • 6The filing also includes the Cover Page Interactive Data File (Exhibit 104).

Frequently Asked Questions

The specific financial results are detailed in the press release furnished as Exhibit 99.1 to this Form 8-K filing, dated February 13, 2025. Investors should refer to this press release for comprehensive information.

Investors should look for key indicators such as revenue generated from Alnylam's commercial products, any updates on pipeline development and clinical trial progress, earnings per share (EPS), cash flow, and any financial guidance provided by the company for future periods.

The information furnished under Item 2.02 of this Form 8-K, including the press release, is generally not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated by reference into other filings, unless specifically stated.